Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor
Colorectal signet‐ring cell carcinoma (SRCC) has been associated with poor survival compared with mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of SRCC and determines...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2015-01, Vol.136 (2), p.333-339 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 2 |
| container_start_page | 333 |
| container_title | International journal of cancer |
| container_volume | 136 |
| creator | Hugen, Niek Verhoeven, Rob H. Lemmens, Valery E van Aart, Carola J. Elferink, Marloes A. Radema, Sandra A. Nagtegaal, Iris D. de Wilt, Johannes H. |
| description | Colorectal signet‐ring cell carcinoma (SRCC) has been associated with poor survival compared with mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of SRCC and determines whether colonic SRCC patients benefit from adjuvant chemotherapy equally compared with MC and AC patients. Data on 196,757 colorectal cancer (CRC) patients in the period 1989–2010 was included in this Dutch nationwide population‐based study. Five‐year relative survival estimates were calculated and multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) were performed. SRCC was found in 1,972 (1.0%) patients. SRCC patients presented more frequently with stage III or IV disease than AC patients (75.2% vs. 43.6%, p |
| doi_str_mv | 10.1002/ijc.28981 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1627984425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1627984425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4881-55136a83d449ec931cf1ee3548a0a61de748bbc3cfb76c1791dd45c5c1f156413</originalsourceid><addsrcrecordid>eNqNkb1OwzAUhS0EoqUw8ALIEgtLWt_Ejh02FPFTVIkF5shxnNZVEhfHAXXjEXhGnoT0BwYmpnul8-nqnHsQOgcyBkLCiVmqcSgSAQdoCCThAQmBHaJhr5GAQxQP0EnbLgkBYIQeo0FIBQURiyFapLayTisvK9yaeaP918enM80cK11VWEmnTGNreY1z3ejSeFw6W2NZLLs32XisFrq2fqGdXK1x3nks8cpah1fOzhvbeqNwKZW37hQdlbJq9dl-jtDL3e1z-hDMnu6n6c0sUFQICBjr7UoRFZQmWiURqBK0jhgVksgYCs2pyHMVqTLnsQKeQFFQppiCElhMIRqhq93d3sFrp1uf1abdZJGNtl2bQRzyRFAasn-g0BugnIc9evkHXdrONX2QDcWTiEOyoS72VJfXushWztTSrbOfd_fAZAe8m0qvf3Ug2abHrO8x2_aYTR_T7RJ9A7KjkB8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1617937192</pqid></control><display><type>article</type><title>Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><creator>Hugen, Niek ; Verhoeven, Rob H. ; Lemmens, Valery E ; van Aart, Carola J. ; Elferink, Marloes A. ; Radema, Sandra A. ; Nagtegaal, Iris D. ; de Wilt, Johannes H.</creator><creatorcontrib>Hugen, Niek ; Verhoeven, Rob H. ; Lemmens, Valery E ; van Aart, Carola J. ; Elferink, Marloes A. ; Radema, Sandra A. ; Nagtegaal, Iris D. ; de Wilt, Johannes H.</creatorcontrib><description>Colorectal signet‐ring cell carcinoma (SRCC) has been associated with poor survival compared with mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of SRCC and determines whether colonic SRCC patients benefit from adjuvant chemotherapy equally compared with MC and AC patients. Data on 196,757 colorectal cancer (CRC) patients in the period 1989–2010 was included in this Dutch nationwide population‐based study. Five‐year relative survival estimates were calculated and multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) were performed. SRCC was found in 1,972 (1.0%) patients. SRCC patients presented more frequently with stage III or IV disease than AC patients (75.2% vs. 43.6%, p < 0.0001) and SRCC was more frequently found in the proximal colon (57.7 vs. 32.0%, p < 0.0001). SRCC patients had a poor 5‐year relative survival of 30.8% (95% CI 28.1–33.6%) in the colon and 19.5% (95% CI 14.7–24.8%) in the rectum compared with 56.8% (95% CI 56.4–57.1%) and 58.5% (95% CI 57.9–59.1%) for AC. This survival difference was found in stage II, but was most prominent in stage III. Compared with AC, there was no significant interaction between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81–1.51), suggesting a comparable benefit from adjuvant chemotherapy in AC and SRCC. In conclusion, the prognostic impact of SRCC is dismal in both colon and rectal cancer patients, but adjuvant chemotherapy is associated with improved survival in AC, MC, and SRCC patients.
What's new?
Signet‐ring cell carcinoma (SRCC), a rare form of colorectal cancer (CRC), is associated with poor prognosis. However, whether that outcome is relevant for both colon and rectal sites remains unclear. Likewise, little is known about the effectiveness of adjuvant therapy in SRCC. This analysis of data on more than 196,000 CRC patients in The Netherlands shows that SRCC patients experience lower 5‐year relative survival, for both colon and rectal sites, compared with adenocarcinoma (AC) patients. Adjuvant chemotherapy for stage III colon carcinoma yielded similar benefits for AC, mucinous adenocarcinoma, and SRCC patients.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.28981</identifier><identifier>PMID: 24841868</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - epidemiology ; Adenocarcinoma - mortality ; Adenocarcinoma, Mucinous - drug therapy ; Adenocarcinoma, Mucinous - epidemiology ; Adenocarcinoma, Mucinous - mortality ; adjuvant chemotherapy ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer ; Carcinoma, Signet Ring Cell - drug therapy ; Carcinoma, Signet Ring Cell - epidemiology ; Carcinoma, Signet Ring Cell - mortality ; Chemotherapy ; Chemotherapy, Adjuvant ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - epidemiology ; Colorectal Neoplasms - mortality ; Combined Modality Therapy ; epidemiology ; Female ; Follow-Up Studies ; Humans ; Male ; Medical prognosis ; Medical research ; Middle Aged ; mucinous carcinoma ; Neoplasm Staging ; Netherlands - epidemiology ; Prognosis ; signet‐ring cell carcinoma ; Survival Rate</subject><ispartof>International journal of cancer, 2015-01, Vol.136 (2), p.333-339</ispartof><rights>2014 UICC</rights><rights>2014 UICC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4881-55136a83d449ec931cf1ee3548a0a61de748bbc3cfb76c1791dd45c5c1f156413</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.28981$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.28981$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24841868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hugen, Niek</creatorcontrib><creatorcontrib>Verhoeven, Rob H.</creatorcontrib><creatorcontrib>Lemmens, Valery E</creatorcontrib><creatorcontrib>van Aart, Carola J.</creatorcontrib><creatorcontrib>Elferink, Marloes A.</creatorcontrib><creatorcontrib>Radema, Sandra A.</creatorcontrib><creatorcontrib>Nagtegaal, Iris D.</creatorcontrib><creatorcontrib>de Wilt, Johannes H.</creatorcontrib><title>Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Colorectal signet‐ring cell carcinoma (SRCC) has been associated with poor survival compared with mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of SRCC and determines whether colonic SRCC patients benefit from adjuvant chemotherapy equally compared with MC and AC patients. Data on 196,757 colorectal cancer (CRC) patients in the period 1989–2010 was included in this Dutch nationwide population‐based study. Five‐year relative survival estimates were calculated and multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) were performed. SRCC was found in 1,972 (1.0%) patients. SRCC patients presented more frequently with stage III or IV disease than AC patients (75.2% vs. 43.6%, p < 0.0001) and SRCC was more frequently found in the proximal colon (57.7 vs. 32.0%, p < 0.0001). SRCC patients had a poor 5‐year relative survival of 30.8% (95% CI 28.1–33.6%) in the colon and 19.5% (95% CI 14.7–24.8%) in the rectum compared with 56.8% (95% CI 56.4–57.1%) and 58.5% (95% CI 57.9–59.1%) for AC. This survival difference was found in stage II, but was most prominent in stage III. Compared with AC, there was no significant interaction between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81–1.51), suggesting a comparable benefit from adjuvant chemotherapy in AC and SRCC. In conclusion, the prognostic impact of SRCC is dismal in both colon and rectal cancer patients, but adjuvant chemotherapy is associated with improved survival in AC, MC, and SRCC patients.
What's new?
Signet‐ring cell carcinoma (SRCC), a rare form of colorectal cancer (CRC), is associated with poor prognosis. However, whether that outcome is relevant for both colon and rectal sites remains unclear. Likewise, little is known about the effectiveness of adjuvant therapy in SRCC. This analysis of data on more than 196,000 CRC patients in The Netherlands shows that SRCC patients experience lower 5‐year relative survival, for both colon and rectal sites, compared with adenocarcinoma (AC) patients. Adjuvant chemotherapy for stage III colon carcinoma yielded similar benefits for AC, mucinous adenocarcinoma, and SRCC patients.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma, Mucinous - drug therapy</subject><subject>Adenocarcinoma, Mucinous - epidemiology</subject><subject>Adenocarcinoma, Mucinous - mortality</subject><subject>adjuvant chemotherapy</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer</subject><subject>Carcinoma, Signet Ring Cell - drug therapy</subject><subject>Carcinoma, Signet Ring Cell - epidemiology</subject><subject>Carcinoma, Signet Ring Cell - mortality</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - epidemiology</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Combined Modality Therapy</subject><subject>epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>mucinous carcinoma</subject><subject>Neoplasm Staging</subject><subject>Netherlands - epidemiology</subject><subject>Prognosis</subject><subject>signet‐ring cell carcinoma</subject><subject>Survival Rate</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkb1OwzAUhS0EoqUw8ALIEgtLWt_Ejh02FPFTVIkF5shxnNZVEhfHAXXjEXhGnoT0BwYmpnul8-nqnHsQOgcyBkLCiVmqcSgSAQdoCCThAQmBHaJhr5GAQxQP0EnbLgkBYIQeo0FIBQURiyFapLayTisvK9yaeaP918enM80cK11VWEmnTGNreY1z3ejSeFw6W2NZLLs32XisFrq2fqGdXK1x3nks8cpah1fOzhvbeqNwKZW37hQdlbJq9dl-jtDL3e1z-hDMnu6n6c0sUFQICBjr7UoRFZQmWiURqBK0jhgVksgYCs2pyHMVqTLnsQKeQFFQppiCElhMIRqhq93d3sFrp1uf1abdZJGNtl2bQRzyRFAasn-g0BugnIc9evkHXdrONX2QDcWTiEOyoS72VJfXushWztTSrbOfd_fAZAe8m0qvf3Ug2abHrO8x2_aYTR_T7RJ9A7KjkB8</recordid><startdate>20150115</startdate><enddate>20150115</enddate><creator>Hugen, Niek</creator><creator>Verhoeven, Rob H.</creator><creator>Lemmens, Valery E</creator><creator>van Aart, Carola J.</creator><creator>Elferink, Marloes A.</creator><creator>Radema, Sandra A.</creator><creator>Nagtegaal, Iris D.</creator><creator>de Wilt, Johannes H.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20150115</creationdate><title>Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor</title><author>Hugen, Niek ; Verhoeven, Rob H. ; Lemmens, Valery E ; van Aart, Carola J. ; Elferink, Marloes A. ; Radema, Sandra A. ; Nagtegaal, Iris D. ; de Wilt, Johannes H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4881-55136a83d449ec931cf1ee3548a0a61de748bbc3cfb76c1791dd45c5c1f156413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma, Mucinous - drug therapy</topic><topic>Adenocarcinoma, Mucinous - epidemiology</topic><topic>Adenocarcinoma, Mucinous - mortality</topic><topic>adjuvant chemotherapy</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer</topic><topic>Carcinoma, Signet Ring Cell - drug therapy</topic><topic>Carcinoma, Signet Ring Cell - epidemiology</topic><topic>Carcinoma, Signet Ring Cell - mortality</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - epidemiology</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Combined Modality Therapy</topic><topic>epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>mucinous carcinoma</topic><topic>Neoplasm Staging</topic><topic>Netherlands - epidemiology</topic><topic>Prognosis</topic><topic>signet‐ring cell carcinoma</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hugen, Niek</creatorcontrib><creatorcontrib>Verhoeven, Rob H.</creatorcontrib><creatorcontrib>Lemmens, Valery E</creatorcontrib><creatorcontrib>van Aart, Carola J.</creatorcontrib><creatorcontrib>Elferink, Marloes A.</creatorcontrib><creatorcontrib>Radema, Sandra A.</creatorcontrib><creatorcontrib>Nagtegaal, Iris D.</creatorcontrib><creatorcontrib>de Wilt, Johannes H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hugen, Niek</au><au>Verhoeven, Rob H.</au><au>Lemmens, Valery E</au><au>van Aart, Carola J.</au><au>Elferink, Marloes A.</au><au>Radema, Sandra A.</au><au>Nagtegaal, Iris D.</au><au>de Wilt, Johannes H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2015-01-15</date><risdate>2015</risdate><volume>136</volume><issue>2</issue><spage>333</spage><epage>339</epage><pages>333-339</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Colorectal signet‐ring cell carcinoma (SRCC) has been associated with poor survival compared with mucinous adenocarcinoma (MC) and the more common adenocarcinoma (AC). Efficacy of adjuvant chemotherapy in SRCC has never been assessed. This study analyzes the prognostic impact of SRCC and determines whether colonic SRCC patients benefit from adjuvant chemotherapy equally compared with MC and AC patients. Data on 196,757 colorectal cancer (CRC) patients in the period 1989–2010 was included in this Dutch nationwide population‐based study. Five‐year relative survival estimates were calculated and multivariate relative survival analyses using a multiple regression model of relative excess risk (RER) were performed. SRCC was found in 1,972 (1.0%) patients. SRCC patients presented more frequently with stage III or IV disease than AC patients (75.2% vs. 43.6%, p < 0.0001) and SRCC was more frequently found in the proximal colon (57.7 vs. 32.0%, p < 0.0001). SRCC patients had a poor 5‐year relative survival of 30.8% (95% CI 28.1–33.6%) in the colon and 19.5% (95% CI 14.7–24.8%) in the rectum compared with 56.8% (95% CI 56.4–57.1%) and 58.5% (95% CI 57.9–59.1%) for AC. This survival difference was found in stage II, but was most prominent in stage III. Compared with AC, there was no significant interaction between SRCC and adjuvant chemotherapy (RER 1.10, 95% CI 0.81–1.51), suggesting a comparable benefit from adjuvant chemotherapy in AC and SRCC. In conclusion, the prognostic impact of SRCC is dismal in both colon and rectal cancer patients, but adjuvant chemotherapy is associated with improved survival in AC, MC, and SRCC patients.
What's new?
Signet‐ring cell carcinoma (SRCC), a rare form of colorectal cancer (CRC), is associated with poor prognosis. However, whether that outcome is relevant for both colon and rectal sites remains unclear. Likewise, little is known about the effectiveness of adjuvant therapy in SRCC. This analysis of data on more than 196,000 CRC patients in The Netherlands shows that SRCC patients experience lower 5‐year relative survival, for both colon and rectal sites, compared with adenocarcinoma (AC) patients. Adjuvant chemotherapy for stage III colon carcinoma yielded similar benefits for AC, mucinous adenocarcinoma, and SRCC patients.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>24841868</pmid><doi>10.1002/ijc.28981</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2015-01, Vol.136 (2), p.333-339 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1627984425 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - epidemiology Adenocarcinoma - mortality Adenocarcinoma, Mucinous - drug therapy Adenocarcinoma, Mucinous - epidemiology Adenocarcinoma, Mucinous - mortality adjuvant chemotherapy Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Carcinoma, Signet Ring Cell - drug therapy Carcinoma, Signet Ring Cell - epidemiology Carcinoma, Signet Ring Cell - mortality Chemotherapy Chemotherapy, Adjuvant Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - epidemiology Colorectal Neoplasms - mortality Combined Modality Therapy epidemiology Female Follow-Up Studies Humans Male Medical prognosis Medical research Middle Aged mucinous carcinoma Neoplasm Staging Netherlands - epidemiology Prognosis signet‐ring cell carcinoma Survival Rate |
| title | Colorectal signet‐ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T06%3A33%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Colorectal%20signet%E2%80%90ring%20cell%20carcinoma:%20benefit%20from%20adjuvant%20chemotherapy%20but%20a%20poor%20prognostic%20factor&rft.jtitle=International%20journal%20of%20cancer&rft.au=Hugen,%20Niek&rft.date=2015-01-15&rft.volume=136&rft.issue=2&rft.spage=333&rft.epage=339&rft.pages=333-339&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.28981&rft_dat=%3Cproquest_pubme%3E1627984425%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1617937192&rft_id=info:pmid/24841868&rfr_iscdi=true |